- Home
- SNCY vs ARVN Comparison
SNCY vs ARVN Comparison
Compare SNCY & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCY
- ARVN
- Stock Information
- Founded
- SNCY 1982
- ARVN 2015
- Country
- SNCY United States
- ARVN United States
- Employees
- SNCY N/A
- ARVN N/A
- Industry
- SNCY Air Freight/Delivery Services
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- SNCY Consumer Discretionary
- ARVN Health Care
- Exchange
- SNCY Nasdaq
- ARVN Nasdaq
- Market Cap
- SNCY 634.5M
- ARVN 676.2M
- IPO Year
- SNCY 2021
- ARVN 2018
- Fundamental
- Price
- SNCY $12.46
- ARVN $9.72
- Analyst Decision
- SNCY Buy
- ARVN Buy
- Analyst Count
- SNCY 7
- ARVN 23
- Target Price
- SNCY $18.86
- ARVN $17.80
- AVG Volume (30 Days)
- SNCY 921.2K
- ARVN 2.5M
- Earning Date
- SNCY 10-29-2025
- ARVN 11-05-2025
- Dividend Yield
- SNCY N/A
- ARVN N/A
- EPS Growth
- SNCY 28.51
- ARVN N/A
- EPS
- SNCY 1.05
- ARVN N/A
- Revenue
- SNCY $1,106,213,000.00
- ARVN $372,800,000.00
- Revenue This Year
- SNCY $6.16
- ARVN N/A
- Revenue Next Year
- SNCY $9.63
- ARVN N/A
- P/E Ratio
- SNCY $11.87
- ARVN N/A
- Revenue Growth
- SNCY 4.27
- ARVN 299.57
- 52 Week Low
- SNCY $8.10
- ARVN $5.90
- 52 Week High
- SNCY $18.59
- ARVN $28.83
- Technical
- Relative Strength Index (RSI)
- SNCY 58.21
- ARVN 57.25
- Support Level
- SNCY $10.25
- ARVN $9.01
- Resistance Level
- SNCY $11.76
- ARVN $10.18
- Average True Range (ATR)
- SNCY 0.59
- ARVN 0.47
- MACD
- SNCY 0.11
- ARVN -0.03
- Stochastic Oscillator
- SNCY 85.00
- ARVN 62.25
About SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.